Search research articles
Contact Us
Filters
Showing results (21-30 of 114) with videos related to
Page
of 12
Sort By:
Molecular Biosystems
|
May 25, 2016
Protein labelling
Lyn H Jones, Eranthie Weerapana
Future Medicinal Chemistry
|
January 14, 2015
TAK1 selective inhibition: state of the art and future opportunities
Iain Kilty, Lyn H Jones
Pharmaceutical Patent Analyst
|
April 9, 2015
Click chemistry patents and their impact on drug discovery and chemical biology
Hua Xu, Lyn H Jones
Science Translational Medicine
|
April 21, 2017
Clinical chemoproteomics-Opportunities and obstacles
Lyn H Jones, Hendrik Neubert
RSC Medicinal Chemistry
|
November 3, 2022
Covalent drugs targeting histidine - an unexploited opportunity?
Jianwei Che, Lyn H Jones
Future Medicinal Chemistry
|
September 28, 2011
Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease
Adam D Hughes, Lyn H Jones
RSC Medicinal Chemistry
|
January 22, 2021
Structure-based design and analysis of SuFEx chemical probes
Lyn H Jones, Jeffery W Kelly
Clinical Pharmacology and Therapeutics
|
July 3, 2023
Clinical Translation of Targeted Protein Degraders
Nikki R Kong, Lyn H Jones
Progress in Medicinal Chemistry
|
February 7, 2013
Medicinal chemistry of glucagon-like peptide receptor agonists
Lyn H Jones, David A Price
SLAS Discovery : Advancing Life Sciences R & D
|
December 18, 2020
Target Validation Using PROTACs: Applying the Four Pillars Framework
Radosław P Nowak, Lyn H Jones
Page
of 12
Search research articles
Search
Showing results (21-30 of 114) with videos related to
Sort By:
Page
of 12
Molecular Biosystems
|
May 25, 2016
Protein labelling
Lyn H Jones, Eranthie Weerapana
Future Medicinal Chemistry
|
January 14, 2015
TAK1 selective inhibition: state of the art and future opportunities
Iain Kilty, Lyn H Jones
Pharmaceutical Patent Analyst
|
April 9, 2015
Click chemistry patents and their impact on drug discovery and chemical biology
Hua Xu, Lyn H Jones
Science Translational Medicine
|
April 21, 2017
Clinical chemoproteomics-Opportunities and obstacles
Lyn H Jones, Hendrik Neubert
RSC Medicinal Chemistry
|
November 3, 2022
Covalent drugs targeting histidine - an unexploited opportunity?
Jianwei Che, Lyn H Jones
Future Medicinal Chemistry
|
September 28, 2011
Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease
Adam D Hughes, Lyn H Jones
RSC Medicinal Chemistry
|
January 22, 2021
Structure-based design and analysis of SuFEx chemical probes
Lyn H Jones, Jeffery W Kelly
Clinical Pharmacology and Therapeutics
|
July 3, 2023
Clinical Translation of Targeted Protein Degraders
Nikki R Kong, Lyn H Jones
Progress in Medicinal Chemistry
|
February 7, 2013
Medicinal chemistry of glucagon-like peptide receptor agonists
Lyn H Jones, David A Price
SLAS Discovery : Advancing Life Sciences R & D
|
December 18, 2020
Target Validation Using PROTACs: Applying the Four Pillars Framework
Radosław P Nowak, Lyn H Jones
Page
of 12